Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Division of Applied Functional Genomics

Prof. Dr. Claudia Scholl

Cultured immortalized myoblasts differentiated into myocytes.

Our laboratory is studying rare, poorly understood tumor diseases with the goal of finding new entry points for therapies through a better understanding of their biology and pathogenesis.

Rare cancers and ultra-rare sarcomas pose a major problem for affected patients as they are associated with several challenges. Unlike common cancers, only a few patients are available to conduct randomized clinical trials, discover recurrent cancer driver genes, and study the biology of the disease. This leads to lack of scientific knowledge, misdiagnosis and delays in diagnosis, and deficits in clinical expertise and appropriate therapies, which ultimately results in poorer overall survival when comparing rare to common cancers. The relevance of studying these ill-defined cancers also becomes clear when considering the number of patients affected, which overall are not that rare. 22% of all cancers diagnosed each year in Europe are rare, that is one out of five cancers. In addition, 24% of all people living with cancer in Europe have a rare cancer, which are currently 4.3 Million people (

Our strategy to gain insights into the biology of rare cancers is to combine omics analyses of patient samples with functional characterization of tumor-specific alterations. We have a close cooperation with the prospective precision oncology program MASTER (Molecularly Aided Stratification for Tumor Eradication Research), in which patient tumors, in particular rare cancers, are investigated by whole-genome, exome, and RNA sequencing. Genetic alterations discovered in this program are functionally characterized in our laboratory by using different model systems including cell lines and mouse models. In addition, we uncover secondary gene dependencies by using large-scale CRISPR screening that is followed by their in-depth mechanistic characterization. Through these efforts, we provide new mechanistic insights into critical cellular signaling pathways and help translate genomic information into clinical applications.


Prof. Dr. Claudia Scholl
Applied Functional Genomics (B290)
Deutsches Krebsforschungszentrum
Im Neuenheimer Feld 581
69120 Heidelberg
Tel: +49 6221 42 1636

Selected Publications

  • Martins LR, et al. (2024). Single-cell division tracing and transcriptomics reveal cell types and differentiation paths in the regenerating lung. Nat Commun, 15(1):2246
  • Schöpf J, Uhrig S, Heilig CE, Lee KS, et al. (2024). Multi-omic and functional analysis for classification and treatment of sarcomas with FUS-TFCP2 or EWSR1-TFCP2 fusions. Nat Commun 15(1):51
  • Jensen P et al. (2020). Requirement for LIM kinases in acute myeloid leukemia. Leukemia 34:3173-3185
  • Trautmann M & Cheng YY et al. (2019). Requirement for YAP1 signaling in myxoid liposarcoma. EMBO Mol Med 11: e9889.
to top
powered by webEdition CMS